Originally published as JCO Early Release 10.1200/JCO.2002.06.029 on July 1 2002

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chlebowski, R. T. Articles by Pfister, D. G. Search for Related Content PubMed PubMed Citation Articles by Chlebowski, R. T. Articles by Pfister, D. G.

American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition

From the American Society of Clinical Oncology, Alexandria, VA.

Address reprint requests to American Society of Clinical Oncology, Health Services Research Department, 1900 Duke St, Suite 200, Alexandria, VA 22314; email: guidelines{at}asco.orgThis article was published online ahead of print at www.jco.org.

OBJECTIVE: To update an evidence-based technology assessment of chemoprevention strategies for breast cancer risk reduction.

POTENTIAL INTERVENTIONS: Tamoxifen, raloxifene, aromatase inhibition, and fenretinide.

OUTCOMES: Outcomes of interest include breast cancer incidence, breast cancer–specific survival, overall survival, and net health benefit.

EVIDENCE: A comprehensive, formal literature review was conducted for relevant topics. Testimony was collected from invited experts and interested parties. The American Society of Clinical Oncology (ASCO) prescribed technology assessment procedure was followed.

VALUES: More weight was given to published randomized trials.

BENEFITS/HARMS: A woman’s decision regarding breast cancer risk reduction strategies is complex and will depend on the importance and weight attributed to information regarding both cancer- and noncancer-related risks and benefits.

CONCLUSIONS: For women with a defined 5-year projected breast cancer risk of 1.66%, tamoxifen (at 20 mg/d for 5 years) may be offered to reduce their risk. Risk/benefit models suggest that greatest clinical benefit with least side effects is derived from use of tamoxifen in younger (premenopausal) women (who are less likely to have thromboembolic sequelae and uterine cancer), women without a uterus, and women at higher breast cancer risk. Data do not as yet suggest that tamoxifen provides an overall health benefit or increases survival. In all circumstances, tamoxifen use should be discussed as part of an informed decision-making process with careful consideration of individually calculated risks and benefits. Use of tamoxifen combined with hormone replacement therapy or use of raloxifene, any aromatase inhibitor or inactivator, or fenretinide to lower the risk of developing breast cancer is not recommended outside of a clinical trial setting. This technology assessment represents an ongoing process and recommendations will be updated in a timely matter.

VALIDATION: The conclusions were endorsed by the ASCO Health Services Research Committee and the ASCO Board of Directors.

SPONSOR: American Society of Clinical Oncology.

This article has been cited by other articles:

				N. D. Kauff, S. M. Domchek, T. M. Friebel, M. E. Robson, J. Lee, J. E. Garber, C. Isaacs, D. G. Evans, H. Lynch, R. A. Eeles, et al. Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study J. Clin. Oncol., March 10, 2008; 26(8): 1331 - 1337. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. K. Aragaki, T. Rohan, S. Yasmeen, G. Sarto, C. A. Rosenberg, F. A. Hubbell, and For the Women's Health Initiative Investigators Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status J Natl Cancer Inst, November 21, 2007; 99(22): 1695 - 1705. [Abstract] [Full Text] [PDF]

				C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]

				K. Armstrong, E. Moye, S. Williams, J. A. Berlin, and E. E. Reynolds Screening Mammography in Women 40 to 49 Years of Age: A Systematic Review for the American College of Physicians Ann Intern Med, April 3, 2007; 146(7): 516 - 526. [Abstract] [Full Text] [PDF]

				A. Padron, L. Li, E. M. Kofoed, and F. Schaufele Ligand-Selective Interdomain Conformations of Estrogen Receptor-{alpha} Mol. Endocrinol., January 1, 2007; 21(1): 49 - 61. [Abstract] [Full Text] [PDF]

				K. Armstrong, D. A. Quistberg, E. Micco, S. Domchek, and C. Guerra Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med, November 13, 2006; 166(20): 2260 - 2265. [Abstract] [Full Text] [PDF]

				J.-I. Huh, A. Calvo, R. Charles, and J. E. Green Distinct tumor stage-specific inhibitory effects of 2-methoxyestradiol in a breast cancer mouse model associated with id-1 expression. Cancer Res., April 1, 2006; 66(7): 3495 - 3503. [Abstract] [Full Text] [PDF]

				A. U. Buzdar Dietary Modification and Risk of Breast Cancer JAMA, February 8, 2006; 295(6): 691 - 692. [Full Text] [PDF]

				H. Gogas, C. Markopoulos, and R. Blamey Should women be advised to take prophylactic endocrine treatment outside of a clinical trial setting? Ann. Onc., December 1, 2005; 16(12): 1861 - 1866. [Abstract] [Full Text] [PDF]

				B. S. Komm, Y. P. Kharode, P. V. N. Bodine, H. A. Harris, C. P. Miller, and C. R. Lyttle Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity Endocrinology, September 1, 2005; 146(9): 3999 - 4008. [Abstract] [Full Text] [PDF]

				R. J. Santen and R. Mansel Benign Breast Disorders N. Engl. J. Med., July 21, 2005; 353(3): 275 - 285. [Full Text] [PDF]

				E. P. Winer, C. Hudis, H. J. Burstein, A. C. Wolff, K. I. Pritchard, J. N. Ingle, R. T. Chlebowski, R. Gelber, S. B. Edge, J. Gralow, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004 J. Clin. Oncol., January 20, 2005; 23(3): 619 - 629. [Abstract] [Full Text] [PDF]

				J. N. Ingle Endocrine Therapy Trials of Aromatase Inhibitors for Breast Cancer in the Adjuvant and Prevention Settings Clin. Cancer Res., January 15, 2005; 11(2): 900s - 905s. [Abstract] [Full Text] [PDF]

				B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]

				O. Zierau, J. O'Sullivan, C. Morrissey, D. McDonald, W. Wunsche, M. R Schneider, M. P Tenniswood, and G. Vollmer Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus Endocr. Relat. Cancer, December 1, 2004; 11(4): 823 - 830. [Abstract] [Full Text] [PDF]

				C. D. Bushnell and L. B. Goldstein Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis Neurology, October 12, 2004; 63(7): 1230 - 1233. [Abstract] [Full Text] [PDF]

				Breast Cancer Obstet. Gynecol., October 1, 2004; 104(4_suppl): 11S - 16S. [Full Text] [PDF]

				Venous Thromboembolic Disease Obstet. Gynecol., October 1, 2004; 104(4_suppl): 118S - 127S. [Full Text] [PDF]

				N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis Effects of estrogen deprivation due to breast cancer treatment Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535. [Abstract] [Full Text] [PDF]

				S.-Y. Tsang, X. Yao, F. L. Chan, C.-M. Wong, Z.-Y. Chen, I. Laher, and Y. Huang Estrogen and Tamoxifen Modulate Cerebrovascular Tone in Ovariectomized Female Rats Hypertension, July 1, 2004; 44(1): 78 - 82. [Abstract] [Full Text] [PDF]

				K. B. Bouker, T. C. Skaar, D. R. Fernandez, K. A. O'Brien, R. B. Riggins, D. Cao, and R. Clarke Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant) Cancer Res., June 1, 2004; 64(11): 4030 - 4039. [Abstract] [Full Text] [PDF]

				J. Cuzick, A. Buzdar, M. Baum, R. Bianco, R. Coleman, M. Constenla, W. Distler, M. Dowsett, J. Forbes, J. P. Guastalla, et al. Adjuvant Use of Anastrozole in Breast Cancer J. Clin. Oncol., April 15, 2004; 22(8): 1524 - 1526. [Full Text]

				L. C. Hartmann, A. Degnim, and D. J. Schaid Prophylactic Mastectomy for BRCA1/2 Carriers: Progress and More Questions J. Clin. Oncol., March 15, 2004; 22(6): 981 - 983. [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				P. E. Goss and K. Strasser-Weippl Prevention Strategies with Aromatase Inhibitors Clin. Cancer Res., January 1, 2004; 10(1): 372S - 379S. [Abstract] [Full Text] [PDF]

				R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial JAMA, June 25, 2003; 289(24): 3243 - 3253. [Abstract] [Full Text] [PDF]

				H. Meijers-Heijboer, C. T.M. Brekelmans, M. Menke-Pluymers, C. Seynaeve, A. Baalbergen, C. Burger, E. Crepin, A. W.M. van den Ouweland, B. van Geel, and J. G.M. Klijn Use of Genetic Testing and Prophylactic Mastectomy and Oophorectomy in Women With Breast or Ovarian Cancer From Families With a BRCA1 or BRCA2 Mutation J. Clin. Oncol., May 1, 2003; 21(9): 1675 - 1681. [Abstract] [Full Text] [PDF]

				B. L. Riggs and L. C. Hartmann Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629. [Full Text] [PDF]

				V. G. Vogel and S. Lo Preventing Hormone-Dependent Breast Cancer in High-Risk Women J Natl Cancer Inst, January 15, 2003; 95(2): 91 - 93. [Full Text] [PDF]

				R. T. Chlebowski and A. McTiernan Biological Significance of Interventions That Change Breast Density J Natl Cancer Inst, January 1, 2003; 95(1): 4 - 5. [Full Text] [PDF]

				V. G. Vogel, J. P. Costantino, D. L. Wickerham, and W. M. Cronin National Surgical Adjuvant Breast and Bowel Project Update: Prevention Trials and Endocrine Therapy of Ductal Carcinoma in Situ Clin. Cancer Res., January 1, 2003; 9(1): 495S - 501S. [Abstract] [Full Text] [PDF]

				E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002 J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327. [Abstract] [Full Text] [PDF]